Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole

Next Previous
Search
Trial Profile

A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary) ; Ribociclib (Primary) ; Goserelin
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RIBECCA
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 15 Dec 2023 Final Results published in the European Journal of Cancer
  • 10 Dec 2022 Results of AI4ANNA study assessing the predictive potential of machine learning methods with respect to tumor control and safety outcomes using German study data (RIBECCA; n=487, RIBANNA; n=1904) and toidentify the most relevant baseline factors for prediction, presented at the 45th Annual San Antonio Breast Cancer Symposium.
  • 22 Dec 2021 Results (n=40) of preplanned exploratory subanalysis investigating peripheral immune responses to ribociclib in patients with metastatic HR+ breast cancer, published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top